Use of jackknife influence profiles in bioequivalence evaluations

Pharmaceutical Science and Technology Today

Volumn 2, Issue 4, 1999, Pages 152-159

  Wang, Yibin ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

BIOAVAILABILITY; BIOEQUIVALENCE; CONTROLLED DRUG RELEASE; DECISION MAKING; DELAYED DRUG RELEASE; DIAGNOSTIC PROCEDURE; REVIEW; STATISTICS;

EID: 0033120492     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(99)00138-8     Document Type: Review

References (33)

1. 1 Canadian Health Protection Branch (HPB) (1991) Drugs Directorate Policy: CI Standard for Comparative Bioavailability, Ottawa, ON, Canada
2. 2 CPMP Commission of the European Communities (1992) Guidance: Investigation of Bioavailability and Bioequivalence
3. 3 Food and Drug Administration (1992) Guidance on Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design, informal communication by the Division of Bioequivalence, Office of Generic Drugs, Rockville, MD, USA
4. 4 Nation, R.L. and Sansom, L.N. (1994) Pharmacol. Ther. 62, 41-55
5. 5 Westlake, W.J. (1988) in Biopharmaceutical Statistics for Drug Development (Peace, K.E., ed.), pp. 329-352, Marcel Dekker
6. 6 Chow, S.C. and Liu, J.P. (1994) Drug Inf. J. 28, 851-864
7. 7 Chow, S.C. and Liu, J.P. (1995) Drug Inf. J. 29, 795-804
8. 8 Grieve, A.P. (1991) Eur. J. Clin. Pharmacol. 40, 201-203
9. 9 Pabst, G. and Jaeger, H. (1990) Eur. J. Clin. Pharmacol. 38, 5-10
10. 10 Goldbillon, J. et al. (1996) Eur. J. Drug Metab. Pharmacokinet. 21, 153-158
11. 11 Wang, Y. and Zhou, S. (1999) J. Biopharm. Stat. 9(1), 179-187
12. 12 Schuirmann, D.J. (1987) J. Pharmacokinet. Biopharm. 15, 657-680
13. 13 Steinijans, V.W. et al. (1995) Drug Inf. J. 29, 1055-1062
14. 14 Schulz, H.U. and Steinijans, V.W. (1991) Int. J. Pharmacol. Ther. Toxicol. 29, 293-298
15. 15 Patnaik, R. et al. (1996) Eur. J. Clin. Pharmacol. 21, 159-164
16. 16 Chow, S.C. and Tse, S.K. (1990) Stat. Med. 9, 549-558
17. 17 Ki, F.Y. et al. (1995) J. Biopharm. Stat. 5(1), 71-94
18. 18 Liu, J.P. and Weng, C.S. (1991) Stat. Med. 10, 1357-1389
19. 19 Frezza, M. et al. (1990) New Engl. J. Med. 322(2), 95-99
20. 20 Benet, L.Z. et al. (1996) in The Pharmacological Basis of Therapeutics (Wonsiewicz, M.J. and McCurdy, P., eds), pp 3-27, McGraw-Hill, New York, NY, USA
21. 21 Camaggi, C.M. et al. (1995) Cancer Chemother. Pharmacol. 36(4), 356-359
22. 22 Diletti, E. et al. (1991) Int. J. Clin. Pharmacol. Ther. Toxicol. 29, 1-8
23. 23 Phillipes, K.E. (1990) J. Pharmacokinet. Biopharm. 18, 137-143
24. 24 Wang, Y. et al. (1998) Int. J. Clin. Pharmacol. Ther. 36, 534-539
25. 25 Lund, R.E. (1975) Technometrics 17, 473-476
26. 26 Beckman, R.J. and Cook, R.D. (1983) Technometrics 25, 119-149
27. 27 Hawkins, D.M. (1980) Identification of Outliers, Chapman & Hall, New York, NY, USA and London, UK
28. 28 Bull, S.B. et al. (1997) Genet. Epidemiol. 14, 965-970
29. 29 Cook, R.D. and Weisberg, S. (1982) Residuals and Influence in Regression, Chapman & Hall, New York, NY, USA and London, UK
30. 30 Wang, Y. et al. (1998) J. Pharm. Res. (Suppl.) 14(11), 433
31. 31 Efron, B. (1982) The Jackknife, the Bootstrap and Other Sampling Plans, SIAM, Bristol, UK
32. 32 SAS Institute Inc. (1990) in SAS/STAT User's Guide (Version 6, Vol. 2, 4th edn), pp. 891-996, SAS Institute Inc., Cary, NC, USA
33. 33 Sauter, R. et al. (1992) Int. J. Pharmacol. Ther. Toxicol. 30, 233-256